Price$3.37-0.00 (-0.15%)
04:00 PM05:45 PM
News · 26 weeks42-46%
2025-12-142026-06-07
Mix3390d
- Other17(52%)
- SEC Filings7(21%)
- Insider4(12%)
- Market2(6%)
- Leadership2(6%)
- M&A1(3%)
Latest news
25 items- PRAclarion Rejects Echo Lake Capital's Unsolicited Acquisition ProposalBROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to a recent communication issued by Echo Lake Capital and its principal, Ephraim Fields. Aclarion's Board of Directors carefully reviewed Echo Lake's unsolicited public proposal and unanimously determined to reject it. The Board believes that the proposal significantly undervalues the Company and its strategic potential. Th
- PRAclarion Stockholders Approve All Proposals at 2026 Annual MeetingBROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026. The approved proposals included the election of Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda Williams to the Board of Directors to serve until the 2027 annual meeting, the ratification of
- SECAclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aclarion, Inc. (0001635077) (Filer)
- PRAclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationExpands availability of Nociscan in the greater Los Angeles area with leading neuroscience groupAdds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., June 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pai
- PRAclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyAward-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back painNociscan's underlying MRS technology enabled measurement of intradiscal propionic acid to uncover immune-linked patient subtypesLatest findings point to potential clinical applications of Nociscan beyond surgical decision support, expanding the future scope of precision spine care BROOMFIELD, Colo., June 01, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify
- PRAclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited ProposalBROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the Company for $4.00 per share in cash and contingent value rights: Aclarion's Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. We regularly review our strategic priorities and evaluate op
- NEWSEcho Lake Capital Offers To Acquire Aclarion Inc.Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse takeoverStock price down 99% since its IPO only four years agoBoard owns few shares so lacks financial incentive to maximize shareholder valueDirectors have been paid $5.6 million or 50% of company's current equity market valueThramann has overseen destruction of shareholder value at Aclarion and Auddia Inc. with both stocks down 99% since their IPOs"Independent" Director Deitsch has been sued for violating securities law and has longstanding relationship with ThramannBelieves certain directors
- SECSEC Form 10-Q filed by Aclarion Inc.10-Q - Aclarion, Inc. (0001635077) (Filer)
- INSIDERDirector Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERChief Executive Officer Ness Brent bought $19,999 worth of shares (6,289 units at $3.18), increasing direct ownership by 57,173% to 6,300 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Wesemann William bought $5,155 worth of shares (1,562 units at $3.30), increasing direct ownership by 156,200% to 1,563 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- PRAclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment"Matching the right procedure to the right patient is what moves the field forward" Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volumeThe CLARITY randomized clinical trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain BROOMFIELD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the locati
- PRAclarion Announces Inducement Grant to New Commercial Director, Western U.S.BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion's board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026. This stock option was
- PRAclarion Announces Second Commercial Agreement with Weill Cornell MedicineBROOMFIELD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by renowned neurosurgeon, Roger Härtl, MD, the founder and dire
- PRAclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical AdoptionTriple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflowsAdvancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwideAnnounced $2.5 million share repurchase programStrong balance sheet, no debt and cash runway into the second half of 2027, reinforcing long-term growth strategy BROOMFIELD, Colo., April 30, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligenc
- PRAclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanCommercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., April 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Dan will lead commercial efforts across
- SECSEC Form DEF 14A filed by Aclarion Inc.DEF 14A - Aclarion, Inc. (0001635077) (Filer)
- SECAclarion Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Aclarion, Inc. (0001635077) (Filer)
- PRAclarion Announces $2.5 Million Stock Repurchase PlanBROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that its Board of Directors has authorized a share repurchase program of up to $2.5 million of the Company's outstanding common stock. Aclarion expects to execute the repurchase program over the next 12 months. The timing, volume, and nature of repurchases will be determined by the Company
- PRAclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back PainPatent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross marginsExpands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat BROOMFIELD, Colo., April 16, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S. Patent #12,601,803, titled "System for Machine Learning-Based Model Training and P
- PRAclarion Receives Pinnacle Award for AI InnovationRecognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has been awarded a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. The award recognizes the company's use of AI in its Nociscan solution for chronic low back pain, one of healthcare's
- PRAclarion Announces Agreement with Weill Cornell MedicineBROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team led by triple-board certified physician and Principal Investigator, Jaspal Ricky Singh, MD, who has earned a national reputati
- PRAclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician VideoVideo featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practiceNearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain BROOMFIELD, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosu
- SECSEC Form PRE 14A filed by Aclarion Inc.PRE 14A - Aclarion, Inc. (0001635077) (Filer)
ACON FAQ
6 questionsWhat does Aclarion Inc. do?
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.Where does ACON stock trade?
Aclarion Inc. (ACON) is listed on NASDAQ.What sector and industry is ACON in?
Aclarion Inc. operates in the Health Care sector, Medical Specialities industry.When did Aclarion Inc. go public?
Aclarion Inc. (ACON) completed its IPO in 2022.What companies are similar to ACON?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare ACON side-by-side with any of them on Quantisnow.How can I track ACON on Quantisnow?
Quantisnow aggregates Aclarion Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACON to receive live email and push alerts on every new disclosure.